The global cancer biomarkers market is projected to grow from $23.22 billion in 2026 to $35.16 billion by 2031, at a CAGR of 8.65%. Growth is fueled by rising cancer prevalence, increased use of personalized medicine, and advances in molecular diagnostics like genomics and liquid biopsies. North America leads the market, while Asia-Pacific shows strong growth potential due to expanding healthcare infrastructure and awareness. Innovations in AI and companion diagnostics are enhancing early detection and treatment precision, improving patient outcomes and reducing healthcare costs.
Wolters Kluwer repurchased 44,119 of its ordinary shares between May 7 and May 13, 2026, spending €2.7 million at an average price of €61.07 per share. This buyback is part of a larger 2026 program aiming to repurchase up to €500 million worth of sha...
The global organic semiconductor market, valued at $184.52 billion in 2025, is projected to grow to $1,175.68 billion by 2035, expanding at a CAGR of 20.35%. Growth is fueled by advances in molecular stacking that enhance energy efficiency and bright...
Top pension officials from New York and California have expressed concerns about SpaceX's upcoming IPO, criticizing its dual-class share structure that grants Elon Musk significant voting power and control. They warn that this 'most management-favora...
Ipsen has introduced corabotase, the first molecule in a new class of recombinant neuro-inhibitors, at the SCALE symposium. Phase II trial data show corabotase's safety and efficacy in treating moderate to severe facial wrinkles, including glabellar ...
Ipsen has introduced corabotase, the first molecule in a new class of recombinant neuroinhibitors, designed to treat moderate to severe upper facial lines such as glabellar lines. Phase II trial data presented at the SCALE Symposium showed corabotase...
